Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions

David R. Elmaleh, Martin R. Farlow, Peter S. Conti, Ronald G. Tompkins, Ljiljana Kundakovic, Rudolph E. Tanzi

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Alzheimer's disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures, heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action, and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving our ability to identify novel therapies for this devastating disease.

Original languageEnglish (US)
Pages (from-to)715-732
Number of pages18
JournalJournal of Alzheimer's Disease
Volume71
Issue number3
DOIs
StatePublished - Jan 1 2019

    Fingerprint

Keywords

  • Alzheimer's disease
  • amyloid-β
  • biomarkers
  • clinical trial design
  • combined modality therapy
  • inflammation
  • selection of subjects
  • tau protein
  • treatment outcomes

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this